The FDA finalized 48 product-specific guidances on how to develop generic drugs that are therapeutically equivalent to certain reference-listed drugs. The guidances are intended to help sponsors identify the most appropriate methodology for developing generics and generating the evidence needed to support approval. Although the ultimate goal is to facilitate the availability of generics, some of the drugs referenced by the final guidances already have a number of approved generics. For instance, one of the guidances addresses diabetes drug acarbose (Precose, Bayer Healthcare Pharmaceuticals Inc.), which was first approved 20 years ago. Since 2008, the FDA has approved seven generic versions of the drug, according to the Orange Book.